View in EDS

Revealing molecular determinants governing mambalgin-3 pharmacology at acid-sensing ion channel 1 variants

Saved in:
Bibliographic Details
Title: Revealing molecular determinants governing mambalgin-3 pharmacology at acid-sensing ion channel 1 variants
Authors: Ben Cristofori-Armstrong, Elena Budusan, Jennifer J. Smith, Steve Reynaud, Kerstin Voll, Irène R. Chassagnon, Thomas Durek, Lachlan Douglas Rash
Source: Cell Mol Life Sci
Cellular and molecular life sciences, vol. 81, no. 1, pp. 266
Publisher Information: Springer Science and Business Media LLC, 2024.
Publication Year: 2024
Subject Terms: Acid Sensing Ion Channels, Elapid Venoms, Models, Molecular, Xenopus laevis, Binding Sites, Animals, Humans, Original Article, Amino Acid Sequence, Acid Sensing Ion Channels/metabolism, Acid Sensing Ion Channels/genetics, Acid Sensing Ion Channels/chemistry, Rats, Elapid Venoms/chemistry, Elapid Venoms/metabolism, Elapid Venoms/pharmacology, Elapid Venoms/genetics, Peptides, ASIC, Allosteric modulation, Electrophysiology, Gating modifier, Ligand selectivity, Protein-protein interaction, Specificity, Venom peptide, 3. Good health
Description: Acid-sensing ion channels (ASICs) are trimeric proton-gated cation channels that play a role in neurotransmission and pain sensation. The snake venom-derived peptides, mambalgins, exhibit potent analgesic effects in rodents by inhibiting central ASIC1a and peripheral ASIC1b. Despite their distinct species- and subtype-dependent pharmacology, previous structure-function studies have focussed on the mambalgin interaction with ASIC1a. Currently, the specific channel residues responsible for this pharmacological profile, and the mambalgin pharmacophore at ASIC1b remain unknown. Here we identify non-conserved residues at the ASIC1 subunit interface that drive differences in the mambalgin pharmacology from rat ASIC1a to ASIC1b, some of which likely do not make peptide binding interactions. Additionally, an amino acid variation below the core binding site explains potency differences between rat and human ASIC1. Two regions within the palm domain, which contribute to subtype-dependent effects for mambalgins, play key roles in ASIC gating, consistent with subtype-specific differences in the peptides mechanism. Lastly, there is a shared primary mambalgin pharmacophore for ASIC1a and ASIC1b activity, with certain peripheral peptide residues showing variant-specific significance for potency. Through our broad mutagenesis studies across various species and subtype variants, we gain a more comprehensive understanding of the pharmacophore and the intricate molecular interactions that underlie ligand specificity. These insights pave the way for the development of more potent and targeted peptide analogues required to advance our understating of human ASIC1 function and its role in disease.
Document Type: Article
Other literature type
File Description: application/pdf
Language: English
ISSN: 1420-9071
1420-682X
DOI: 10.1007/s00018-024-05276-2
DOI: 10.21203/rs.3.rs-4539352/v1
Access URL: https://pubmed.ncbi.nlm.nih.gov/38880807
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_67E5237770C06
https://serval.unil.ch/resource/serval:BIB_67E5237770C0.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_67E5237770C0
Rights: CC BY
Accession Number: edsair.doi.dedup.....4dcbb356515421fef6819aecb4bfb3af
Database: OpenAIRE
Description
Abstract:Acid-sensing ion channels (ASICs) are trimeric proton-gated cation channels that play a role in neurotransmission and pain sensation. The snake venom-derived peptides, mambalgins, exhibit potent analgesic effects in rodents by inhibiting central ASIC1a and peripheral ASIC1b. Despite their distinct species- and subtype-dependent pharmacology, previous structure-function studies have focussed on the mambalgin interaction with ASIC1a. Currently, the specific channel residues responsible for this pharmacological profile, and the mambalgin pharmacophore at ASIC1b remain unknown. Here we identify non-conserved residues at the ASIC1 subunit interface that drive differences in the mambalgin pharmacology from rat ASIC1a to ASIC1b, some of which likely do not make peptide binding interactions. Additionally, an amino acid variation below the core binding site explains potency differences between rat and human ASIC1. Two regions within the palm domain, which contribute to subtype-dependent effects for mambalgins, play key roles in ASIC gating, consistent with subtype-specific differences in the peptides mechanism. Lastly, there is a shared primary mambalgin pharmacophore for ASIC1a and ASIC1b activity, with certain peripheral peptide residues showing variant-specific significance for potency. Through our broad mutagenesis studies across various species and subtype variants, we gain a more comprehensive understanding of the pharmacophore and the intricate molecular interactions that underlie ligand specificity. These insights pave the way for the development of more potent and targeted peptide analogues required to advance our understating of human ASIC1 function and its role in disease.
ISSN:14209071
1420682X
DOI:10.1007/s00018-024-05276-2